GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Dividend Yield %

EYPT (EyePoint Pharmaceuticals) Dividend Yield % : 0.00% (As of Dec. 13, 2024)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Dividend Yield %?

As of today (2024-12-13), the Trailing Annual Dividend Yield of EyePoint Pharmaceuticals is 0.00%.

The historical rank and industry rank for EyePoint Pharmaceuticals's Dividend Yield % or its related term are showing as below:

EYPT's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.42
* Ranked among companies with meaningful Dividend Yield % only.

EyePoint Pharmaceuticals's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00.

As of today (2024-12-13), the Forward Dividend Yield % of EyePoint Pharmaceuticals is 0.00%.

EyePoint Pharmaceuticals's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


EyePoint Pharmaceuticals Dividend Yield % Historical Data

The historical data trend for EyePoint Pharmaceuticals's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Dividend Yield % Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EyePoint Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Dividend Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EyePoint Pharmaceuticals's Dividend Yield %

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Dividend Yield % falls into.



EyePoint Pharmaceuticals Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


EyePoint Pharmaceuticals  (NAS:EYPT) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


EyePoint Pharmaceuticals Dividend Yield % Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Executives
Goran Ando director
Wendy F Dicicco director
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Nancy Lurker director, officer: President and CEO PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
David R Guyer director ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
David Scott Jones officer: SVP & Chief Commercial Officer C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
Dario A. Paggiarino officer: Chief Medical Officer 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Ye Liu director ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Michael Craig Pine officer: Chief Corp Dev.&Strat. Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p. 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Anthony P Adamis director 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension 10 percent owner 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston officer: Chief Financial Officer 124 CHATHAM STREET, CHATHAM NJ 07928
John B. Landis director 1700 KENT AVENUE, WEST LAFAYETTE IN 46906